| Today’s Big NewsMar 14, 2024 |
|
March 18-20, 2024 | Savannah, GA
The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer.
Secure 50% off Your Fierce TMF Summit Pass | LIMITED Passes Available: Use Promo Code LASTCHANCE.
Secure your spot Today!
 |
|
| By Nick Paul Taylor AstraZeneca is paying $800 million to expand into rare endocrinology, snagging itself a phase 3 candidate through the acquisition of French biotech Amolyt Pharma. The deal features $250 million in milestones tied to a regulatory event. |
|
|
|
By Max Bayer Genmab, coming off one of its most successful years since its inception, is transitioning to a fully integrated pharma company. The antibody maker has seen revenue quadruple since 2019. |
By Eric Sagonowsky As CDMO giants Wuxi AppTec and WuXi Biologics come under mounting scrutiny for their alleged ties to Chinese government officials, they are losing a key ally in Washington, D.C. |
By Max Bayer Astellas is ending a partnership with Cartesian and its preclinical asset, Xork. The Japanese pharma licensed the asset in January 2023, back when it was being developed by Selecta Biosciences. |
|
Protect performance with a high-purity RNase Inhibitor that preserves RNA at elevated temperatures. Maintain accurate transcript abundance with a high-efficiency, low-bias cDNA amplification polymerase. 
|
|
By James Waldron The antibody-drug conjugate craze shows no signs of slowing down any time soon, judging by Tubulis’ latest financing. |
By James Waldron Spruce Biosciences' stock has shed three-quarters of its value in the wake of the failure of a phase 2 trial for the biotech's only drug candidate. |
By Gabrielle Masson OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic alternatives. |
By Helen Floersh A new oral drug developed by Stanford University researchers may be superior to Pfizer’s Paxlovid at reducing the severity COVID-19, at least in mice. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Helen Floersh TFS HealthScience is growing Down Under, setting up a new operational base in Melbourne, Australia—the CRO's first official location in the Asia Pacific (APAC) region. |
By Angus Liu Ahead of an important advisory committee meeting, the FDA has raised concerns about early trial deaths for multiple myeloma cell therapies. At the meeting, experts will discuss applications that aim to move the CAR-T therapies Carvykti and Abecma into earlier lines of treatment. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
